Latest Biomarin Pharmaceutical Inc (BMRN) Headline
Post# of 106
Posted On: 03/12/2014 6:41:37 PM
Latest Biomarin Pharmaceutical Inc (BMRN) Headlines
BioMarin Pharmaceutical Falls 1.91% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Mar 05, 4:32PM CST
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $78.58 to a high of $79.90. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $79.17 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BioMarin Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Mar 05, 7:00AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the pricing on March 4, 2014 of an underwritten public offering of 1,500,000 shares of its common stock. The gross proceeds to BioMarin from this offering are expected to be approximately $119.3 million before deducting underwriting discounts and commissions and estimated offering expenses payable by BioMarin. The offering is expected to close on or about March 10, 2014, subject to the satisfaction of customary closing conditions. BioMarin intends to use the net proceeds from the offering primarily for the purchase of its corporate headquarters for $116.5 million, which the company expects to close in the first quarter of 2014, and for general corporate purposes. The number of shares being offered constitutes slightly more than 1% of the number of shares of common stock outstanding as of December 31, 2013.
BioMarin Announces Public Offering of Common Stock
GlobeNewswire - Tue Mar 04, 3:22PM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of 1,500,000 shares of its common stock in an underwritten public offering. BioMarin intends to use the net proceeds from the offering primarily for the purchase of its corporate headquarters for $116.5 million, which the company expects to close in the first quarter of 2014, and for general corporate purposes. The number of shares being offered constitutes slightly more than 1% of the number of shares of common stock outstanding as of December 31, 2013.
BioMarin to Present at the Barclays Global Healthcare Conference in Miami
GlobeNewswire - Tue Mar 04, 7:01AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that Dan Oppenheimer, Group Vice President, Development and Portfolio Strategy will present at the Barclays Global Healthcare Conference on March 12 at 9:00am ET. To access the live webcast, please visit the Investor section of the BioMarin website, www.BMRN.com. A replay will be archived on the site for at least one week following the event.
BioMarin Pharmaceutical, Inc.: Is This Orphan Drug Specialist Overvalued?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Mar 03, 2:11PM CST
It's not easy to develop treatments for rare diseases, but it is hard to argue with the rewards. Prior to its acquisition by Sanofi , Genzyme had already established itself as an important player in enzyme replacement therapies, and Shire and ...
Batten Disease - Pipeline Review, H1 2014 Research Report
M2 - Mon Mar 03, 2:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/ntv56s/batten_disease) has announced the addition of the "Batten Disease - Pipeline Review, H1 2014" report to their offering. 'Batten Disease - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Batten Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Batten Disease. Batten Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources Scope - A snapshot of the global therapeutic scenario for Batten Disease. - A review of the Batten Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Batten Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Batten Disease Overview Therapeutics Development Clinical Stage Products Early Stage Products Batten Disease - Products under Development by Companies Batten Disease - Products under Investigation by Universities/Institutes Batten Disease - Companies Involved in Therapeutics Development Batten Disease - Therapeutics Assessment Drug Profiles cysteamine [acetylcysteine] - Drug Profile BMN-190 - Drug Profile Gene Therapy To Activate Tripeptidyl Peptidase 1 For Batten Disease - Drug Profile Gene Therapy Bone Marrow Transplantation - Drug Profile Batten Disease Program - Drug Profile Featured News & Press Releases Appendix Companies Mentioned BioMarin Pharmaceutical Inc. ReGenX Biosciences, LLC Seneb BioSciences, Inc. For more information visit http://www.researchandmarkets.com/research/nt...en_disease About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Watch for BioMarin Pharmaceutical to Potentially Rebound After Falling 2.74% Yesterday
Comtex SmarTrend(R) - Fri Feb 28, 5:14PM CST
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $79.70 to a high of $83.92. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of $79.86 on volume of 2.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Shares of BMRN Up 13.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Feb 27, 9:30AM CST
SmarTrend identified an Uptrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on February 12th, 2014 at $72.26. In approximately 2 weeks, BioMarin Pharmaceutical has returned 13.09% as of today's recent price of $81.71.
Loss at BioMarin Narrower Than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:50AM CST
BioMarin reported narrower than expected loss in the fourth quarter.
BioMarin Announces Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Wed Feb 26, 3:09PM CST
Total Revenue Grows 9.5% in 2013
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 26, 9:26AM CST
Last week was marked by label expansion and mixed results on pipeline candidates.
Insider Trading Alert - KMI, BMRN And ACAS Traded By Insiders
at The Street - Tue Feb 25, 9:30AM CST
Stocks with insider trader activity include KMI, BMRN and ACAS
BioMarin to Present at the Cowen Healthcare Conference in Boston
GlobeNewswire - Tue Feb 25, 7:10AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that Dan Maher, Senior Vice President, Product Development will present at the Cowen and Company 34 Annual Healthcare Conference on March 4 at 11:20am ET. To access the live webcast, please visit the Investor section of the BioMarin website, www.BMRN.com. A replay will be archived on the site for at least one week following the event.
Can Alexion Pharmaceuticals Remain a Top Orphan Drugmaker in the Years Ahead?
Cory Renauer, The Motley Fool - Motley Fool - Mon Feb 24, 1:00PM CST
Orphan drugmakers focus on developing drugs for rare diseases, but unfortunately many companies in this space never become profitable. Of those that do, few are able to succeed like Alexion Pharmaceuticals has. Let's take a look at just how well it...
BioMarin Pharmaceutical Inc: The Future Looks Bright
George Budwell, The Motley Fool - Motley Fool - Sun Feb 23, 4:10PM CST
Orphan drug specialist BioMarin Pharmaceutical enjoyed a notable week. It started with the U.S. Food and Drug Administration, or FDA, officially approving the company's enzyme replacement therapy for Morquio A syndrome called Vimizm. And the...
BioMarin Rises on Favorable CHMP Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 2:05PM CST
The CHMP recommended Vimizim's approval in the EU.
Biotech Breakout: How to Trade BioMarin
at The Street - Fri Feb 21, 5:00AM CST
BioMarin was rising on unusual volume on Thursday. Here's how to trade it today.
BioMarin Pharmaceutical receives recommendation for VIMIZIM
M2 - Fri Feb 21, 4:41AM CST
US-based biopharmaceutical company BioMarin Pharmaceutical (NasdaqGS:BMRN) revealed on Thursday that it has received a positive opinion from the Marketing Authorisation Application (MAA) for VIMIZIM (elosulfase alfa) for the treatment of Morquio A syndrome.
Look for Shares of BioMarin Pharmaceutical to Potentially Pullback after Yesterday's 4.95% Rise
Comtex SmarTrend(R) - Thu Feb 20, 4:06PM CST
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $76.53 to a high of $80.56. Yesterday, the shares gained 5.0%, which took the trading range above the 3-day high of $77.00 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BioMarin Receives Positive Opinion From the CHMP in the European Union for VIMIZIM(TM) (elosulfase alfa) for Morquio A Syndrome
GlobeNewswire - Thu Feb 20, 10:22AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the company's Marketing Authorization Application (MAA) for VIMIZIM(TM) (elosulfase alfa) for the treatment of Morquio A syndrome, also called Mucopolysaccharidosis Type IVA (MPS IVA). The CHMP's recommendation is now referred to the European Commission (EC). If approved by the EC, BioMarin would receive marketing authorization for VIMIZIM in all EU Member States. The EC is expected to render a final decision for VIMIZIM in the second quarter of 2014.
BioMarin Pharmaceutical Falls 1.91% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Mar 05, 4:32PM CST
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $78.58 to a high of $79.90. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $79.17 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BioMarin Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Mar 05, 7:00AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the pricing on March 4, 2014 of an underwritten public offering of 1,500,000 shares of its common stock. The gross proceeds to BioMarin from this offering are expected to be approximately $119.3 million before deducting underwriting discounts and commissions and estimated offering expenses payable by BioMarin. The offering is expected to close on or about March 10, 2014, subject to the satisfaction of customary closing conditions. BioMarin intends to use the net proceeds from the offering primarily for the purchase of its corporate headquarters for $116.5 million, which the company expects to close in the first quarter of 2014, and for general corporate purposes. The number of shares being offered constitutes slightly more than 1% of the number of shares of common stock outstanding as of December 31, 2013.
BioMarin Announces Public Offering of Common Stock
GlobeNewswire - Tue Mar 04, 3:22PM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of 1,500,000 shares of its common stock in an underwritten public offering. BioMarin intends to use the net proceeds from the offering primarily for the purchase of its corporate headquarters for $116.5 million, which the company expects to close in the first quarter of 2014, and for general corporate purposes. The number of shares being offered constitutes slightly more than 1% of the number of shares of common stock outstanding as of December 31, 2013.
BioMarin to Present at the Barclays Global Healthcare Conference in Miami
GlobeNewswire - Tue Mar 04, 7:01AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that Dan Oppenheimer, Group Vice President, Development and Portfolio Strategy will present at the Barclays Global Healthcare Conference on March 12 at 9:00am ET. To access the live webcast, please visit the Investor section of the BioMarin website, www.BMRN.com. A replay will be archived on the site for at least one week following the event.
BioMarin Pharmaceutical, Inc.: Is This Orphan Drug Specialist Overvalued?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Mar 03, 2:11PM CST
It's not easy to develop treatments for rare diseases, but it is hard to argue with the rewards. Prior to its acquisition by Sanofi , Genzyme had already established itself as an important player in enzyme replacement therapies, and Shire and ...
Batten Disease - Pipeline Review, H1 2014 Research Report
M2 - Mon Mar 03, 2:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/ntv56s/batten_disease) has announced the addition of the "Batten Disease - Pipeline Review, H1 2014" report to their offering. 'Batten Disease - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Batten Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Batten Disease. Batten Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources Scope - A snapshot of the global therapeutic scenario for Batten Disease. - A review of the Batten Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Batten Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Batten Disease Overview Therapeutics Development Clinical Stage Products Early Stage Products Batten Disease - Products under Development by Companies Batten Disease - Products under Investigation by Universities/Institutes Batten Disease - Companies Involved in Therapeutics Development Batten Disease - Therapeutics Assessment Drug Profiles cysteamine [acetylcysteine] - Drug Profile BMN-190 - Drug Profile Gene Therapy To Activate Tripeptidyl Peptidase 1 For Batten Disease - Drug Profile Gene Therapy Bone Marrow Transplantation - Drug Profile Batten Disease Program - Drug Profile Featured News & Press Releases Appendix Companies Mentioned BioMarin Pharmaceutical Inc. ReGenX Biosciences, LLC Seneb BioSciences, Inc. For more information visit http://www.researchandmarkets.com/research/nt...en_disease About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Watch for BioMarin Pharmaceutical to Potentially Rebound After Falling 2.74% Yesterday
Comtex SmarTrend(R) - Fri Feb 28, 5:14PM CST
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $79.70 to a high of $83.92. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of $79.86 on volume of 2.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Shares of BMRN Up 13.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Feb 27, 9:30AM CST
SmarTrend identified an Uptrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on February 12th, 2014 at $72.26. In approximately 2 weeks, BioMarin Pharmaceutical has returned 13.09% as of today's recent price of $81.71.
Loss at BioMarin Narrower Than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:50AM CST
BioMarin reported narrower than expected loss in the fourth quarter.
BioMarin Announces Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Wed Feb 26, 3:09PM CST
Total Revenue Grows 9.5% in 2013
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 26, 9:26AM CST
Last week was marked by label expansion and mixed results on pipeline candidates.
Insider Trading Alert - KMI, BMRN And ACAS Traded By Insiders
at The Street - Tue Feb 25, 9:30AM CST
Stocks with insider trader activity include KMI, BMRN and ACAS
BioMarin to Present at the Cowen Healthcare Conference in Boston
GlobeNewswire - Tue Feb 25, 7:10AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that Dan Maher, Senior Vice President, Product Development will present at the Cowen and Company 34 Annual Healthcare Conference on March 4 at 11:20am ET. To access the live webcast, please visit the Investor section of the BioMarin website, www.BMRN.com. A replay will be archived on the site for at least one week following the event.
Can Alexion Pharmaceuticals Remain a Top Orphan Drugmaker in the Years Ahead?
Cory Renauer, The Motley Fool - Motley Fool - Mon Feb 24, 1:00PM CST
Orphan drugmakers focus on developing drugs for rare diseases, but unfortunately many companies in this space never become profitable. Of those that do, few are able to succeed like Alexion Pharmaceuticals has. Let's take a look at just how well it...
BioMarin Pharmaceutical Inc: The Future Looks Bright
George Budwell, The Motley Fool - Motley Fool - Sun Feb 23, 4:10PM CST
Orphan drug specialist BioMarin Pharmaceutical enjoyed a notable week. It started with the U.S. Food and Drug Administration, or FDA, officially approving the company's enzyme replacement therapy for Morquio A syndrome called Vimizm. And the...
BioMarin Rises on Favorable CHMP Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 2:05PM CST
The CHMP recommended Vimizim's approval in the EU.
Biotech Breakout: How to Trade BioMarin
at The Street - Fri Feb 21, 5:00AM CST
BioMarin was rising on unusual volume on Thursday. Here's how to trade it today.
BioMarin Pharmaceutical receives recommendation for VIMIZIM
M2 - Fri Feb 21, 4:41AM CST
US-based biopharmaceutical company BioMarin Pharmaceutical (NasdaqGS:BMRN) revealed on Thursday that it has received a positive opinion from the Marketing Authorisation Application (MAA) for VIMIZIM (elosulfase alfa) for the treatment of Morquio A syndrome.
Look for Shares of BioMarin Pharmaceutical to Potentially Pullback after Yesterday's 4.95% Rise
Comtex SmarTrend(R) - Thu Feb 20, 4:06PM CST
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $76.53 to a high of $80.56. Yesterday, the shares gained 5.0%, which took the trading range above the 3-day high of $77.00 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BioMarin Receives Positive Opinion From the CHMP in the European Union for VIMIZIM(TM) (elosulfase alfa) for Morquio A Syndrome
GlobeNewswire - Thu Feb 20, 10:22AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the company's Marketing Authorization Application (MAA) for VIMIZIM(TM) (elosulfase alfa) for the treatment of Morquio A syndrome, also called Mucopolysaccharidosis Type IVA (MPS IVA). The CHMP's recommendation is now referred to the European Commission (EC). If approved by the EC, BioMarin would receive marketing authorization for VIMIZIM in all EU Member States. The EC is expected to render a final decision for VIMIZIM in the second quarter of 2014.
(0)
(0)BioMarin Pharmaceutical Inc. (BMRN) Stock Research Links
Scroll down for more posts ▼